Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 803-808

  Hiwarkar, P ^a   Gaspar, H B ^a   Gilmour, K ^a   Jagani, M ^a   Chiesa, R ^a   Bennett Rees, N ^a   Breuer, J ^a   Rao, K ^a   Cale, C ^a   Goulden, N ^a   Davies, G ^a   Amrolia, P ^a   Veys, P ^a   Qasim, W ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

ADV; CMV; EBV; haematopoietic SCT; viral reactivations

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROBENECID; RITUXIMAB; THYMOCYTE ANTIBODY;

ADENOVIRUS INFECTION; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DRUG COST; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFANT; INFECTION PREVENTION; LENGTH OF STAY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SURVIVAL PREDICTION; VIRUS CELL INTERACTION; VIRUS REACTIVATION;

ADOLESCENT; ALLOGRAFTS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DNA VIRUS INFECTIONS; DNA VIRUSES; FEMALE; GENETIC DISEASES, INBORN; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LENGTH OF STAY; LYMPHOPENIA; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84879076574     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.221     Document Type: Article

References (26)

1. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.
2. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
3. Chakrabarti S, Hale G, Waldmann H. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? Transplant Proc 2004; 36: 1225-1227.
4. Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumabbased conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 564-570.
5. Miller W, Flynn P, McCullough J, Balfour Jr HH, Goldman A, Haake R et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162-1167.
6. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
7. Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981-987.
8. Lucas KG, Pollok KE, Emanuel DJ. Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 1997; 25: 1-8.
9. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619-1627.
10. Howard DS, Phillips GL, Reece DE, Munn RK, Henslee-Downey J, Pittard M et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29: 1494-1501.
11. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
12. Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4\+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012; 156: 656-666.
13. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load4or 10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006; 37: 51-56.
14. Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155: 377-385.
15. Guerrero A, Riddell SR, Storek J, Stevens-Ayers T, Storer B, Zaia JA et al. Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant 2012; 18: 66-75.
16. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reducedintensity conditioning. Br J Haematol 2005; 129: 229-239.
17. Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother 2012; 67: 1486-1492.
18. Kampmann B, Cubitt D, Walls T, Naik P, Depala M, Samarasinghe S et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005; 130: 595-603.
19. Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116: 5476-5485.
20. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
21. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283-4292.
22. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377.
23. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
24. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52: 49-57.
25. Chatziandreou I, Gilmour KC, McNicol AM, Costabile M, Sinclair J, Cubitt D et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol 2007; 136: 117-126.
26. Comoli P, Schilham MW, Basso S, van Vreeswijk T, Bernardo ME, Maccario R et al. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 2008; 31: 529-536.